Liposome-entrapped topoisomerase inhibitors

Details Liposome-entrapped topoisomerase inhibitors Liposome-entrapped topoisomerase inhibitors

2007-07-17

2007-07-17

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

Reexamination Certificate

active

10230796

ABSTRACT:
A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0.10 μmole drug per μmole lipid.

REFERENCES:
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5192549 (1993-03-01), Barenolz et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5244903 (1993-09-01), Wall et al.
patent: 5395619 (1995-03-01), Zalipsky et al.
patent: 5552156 (1996-09-01), Burke
patent: 5631018 (1997-05-01), Zalipsky et al.
patent: 5891468 (1999-04-01), Martin
patent: 6110491 (2000-08-01), Kirpotin
patent: 6355268 (2002-03-01), Slater et al.
patent: 6465008 (2002-10-01), Slater et al.
patent: WO 86/01102 (1986-02-01), None
patent: WO 94/26253 (1994-11-01), None
patent: WO 95/08986 (1995-04-01), None
patent: WO 98/07409 (1998-02-01), None
patent: WO 98/17256 (1998-04-01), None
patent: WO 98/18450 (1998-05-01), None
patent: WO 99/13816 (1999-03-01), None
Clements, M.K., et al., “Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cellsin vitro” Anti-Cancer Drugs7:851-857 (1996).
Daoud, S.S., et al., “Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts”Anti-Cancer Drugs6:83-93 (1995).
Emerson, D.L., et al., “NX-211, A liposomal formulation of Lurtotecan demonstrates enhanced Pharmacokinetic and antitumor activity”Proc. American Assoc. Cancer Research39:278 (1998) (abstract #1897).
Lundberg, B.B., “Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions”Anti-Cancer Drug Design13:453-461 (1998).
Lynam, E., et al., “Camptothecin analogue efficacy in vitro: Effect of liposomal encapsulation of G1147211C (Lurtotecan) onin vitrocytotoxicity for multiple tumor cell types”Proc. American Assoc. Cancer Research39:421 (1998) (abstract #2863).
Madden, T.D., et al., “Encapsulation of topotecan in lipid-based carrier systems. Evaluation of drug stability and plasma elimination in a murine model, and comparison of antitumor efficacy against murine L1210 and B16 tumors”Proc. of ASCO 17:abstract #754 (1998).
Subramanian, D., and Muller, M.T., “Liposomal Encapsulation Increases the Activity of the Topoisomerase I Inhibitor Topotecan”Oncology Research7(9):461-469 (1995).
Sadzuka, Y., et al., “Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11” Cancer Letters 127:99-106 (1998).
Zhu, G., et al., “The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity”Cancer Chemother Pharmacol39:138-142 (1996).
Deamer, D. W. et al., The Response of Fluorescent Amines to pH Gradients Across Liposome Membranes,Biochim. Biophys. Acta, 274, 323-335, (1972).
Kanzawa, F. et al., Antitumor Activites of a New Indolocarbazole Substance, NB-506, and Establishment of NB-506-resistant Cell Lines, SBC-3/NB, Cancer Res., 55(13):2806-2813, (1995).
Katzung, B., “Basic and Clinical Pharmacology”, 7thEd., (Appleton & Lang. Stamford, CT) p. 882, (1989).
Kunimoto, T. et al., Antitumor Activity of a New Camptothecin Derivative, SN-22, Against Various Murine Tumors, J. Pharmacobio-Dyn., 10(3):148-151, (1987).
Riou, J.F. et al.,Inhibition of Eukaryotic DNA Topoisomerase I and II Activites by Indoloquinolinedione Derivatives, Mol. Pharmacol., 40(5):699-706, (1991).
Rothenberg, M.L. et al., Topoisomerase I Inhibitors: Review and update, Ann. Oncol., 8(9):837-855, (1997).
Sawanda, S. et al., Chemical Modification of an Antitumor Alkaloid, 20(s)-Camptothecin: E-Lactone Ring-Modified Water-Soluble Derivatives of 7-Ethylcamptothecin, Chem. Pharm. Bull., 41(2):310-313, (1993).
Szoka, F. et al., Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes), Ann. Rev. Biophys. Bioeng., 9:467, (1980).
Utsugi, T. et al., Antitumor Activy of Novel Quinoline Derivative, TAS-103, with Inhibitory Effects on Topoisomerases I and II, Jpn. J. Cancer Res., 88(10):992-1002, 1997.
Wall, M.E. et al., Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor fromCamptotheca acuminate, J.Am Chem. Soc., 94:388, (1966).
Zamboni, W. et al., Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma, Cancer Chemother Pharmacol, 53:329-336 (2004).
Stewart and Ratain, Section 6: Topoisomerase Interactive Agents, pp. 415-430, in Cancer Principles & Practice of Oncology, 6thEdition, Lippincott Williams & Wilkins, Philadelphia PA, 2001.
Bridewell et al., Differential Actions of Aclarubicin and Doxorubicin: The Role of Topoisomerase I, Oncology Research, 9:535-542, 1997.
Burke and Gao, Stabilization of Topotecan in Low pH Liposomes Composed of Distearoylphosphatidylcholine, Journal of Pharmaceutical Sciences, 83(7):967-969, 1994.
Burke et al., Lipid Bilayer Partitioning and Stability of Camptothecin Drugs, Biochemistry, 32(20):5352-5364, 1993.
Wassermann et al., Effects of Morpholinyl Doxorubicins, Doxorubicin, and Actinomycin D on Mammalian DNA Topoisomerases I and II, Molecular Pharmacology, 38:38-45, 1990.

Affiliated with

Also associated with

Rating

Liposome-entrapped topoisomerase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposome-entrapped topoisomerase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposome-entrapped topoisomerase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3785382